Reference
Achari, A. E., & Jain, S. K. (2017). Adiponectin, a Therapeutic Target
for Obesity, Diabetes, and Endothelial Dysfunction. Int J Mol Sci,
18 (6). doi:10.3390/ijms18061321
Ahuja, A., Kim, E., Sung, G. H., & Cho, J. Y. (2020). STAT3
Differentially Regulates TLR4-Mediated Inflammatory Responses in Early
or Late Phases. Int J Mol Sci, 21 (20). doi:10.3390/ijms21207675
Akimoto, M., Maruyama, R., Kawabata, Y., Tajima, Y., & Takenaga, K.
(2018). Antidiabetic adiponectin receptor agonist AdipoRon suppresses
tumour growth of pancreatic cancer by inducing RIPK1/ERK-dependent
necroptosis. Cell Death Dis, 9 (8), 804.
doi:10.1038/s41419-018-0851-z
Awazawa, M., Ueki, K., Inabe, K., Yamauchi, T., Kubota, N., Kaneko, K.,
. . . Kadowaki, T. (2011). Adiponectin enhances insulin sensitivity by
increasing hepatic IRS-2 expression via a macrophage-derived
IL-6-dependent pathway. Cell Metab, 13 (4), 401-412.
doi:S1550-4131(11)00083-0 [pii]
10.1016/j.cmet.2011.02.010
Balasubramanian, P., Schaar, A. E., Gustafson, G. E., Smith, A. B.,
Howell, P. R., Greenman, A., . . . Anderson, R. M. (2022). Adiponectin
receptor agonist AdipoRon improves skeletal muscle function in aged
mice. Elife, 11 . doi:10.7554/eLife.71282
Bogacka, I., Xie, H., Bray, G. A., & Smith, S. R. (2005). Pioglitazone
induces mitochondrial biogenesis in human subcutaneous adipose tissue in
vivo. Diabetes, 54 (5), 1392-1399. doi:10.2337/diabetes.54.5.1392
Browning, J. D., Baker, J. A., Rogers, T., Davis, J., Satapati, S., &
Burgess, S. C. (2011). Short-term weight loss and hepatic triglyceride
reduction: evidence of a metabolic advantage with dietary carbohydrate
restriction. Am J Clin Nutr, 93 (5), 1048-1052.
doi:10.3945/ajcn.110.007674
Cheng, A. Y., & Fantus, I. G. (2005). Oral antihyperglycemic therapy
for type 2 diabetes mellitus. CMAJ, 172 (2), 213-226.
doi:10.1503/cmaj.1031414
Choi, H. M., Doss, H. M., & Kim, K. S. (2020). Multifaceted
Physiological Roles of Adiponectin in Inflammation and Diseases.Int J Mol Sci, 21 (4). doi:10.3390/ijms21041219
Coughlan, K. A., Valentine, R. J., Ruderman, N. B., & Saha, A. K.
(2014). AMPK activation: a therapeutic target for type 2 diabetes?Diabetes Metab Syndr Obes, 7 , 241-253. doi:10.2147/DMSO.S43731
Daryabor, G., Atashzar, M. R., Kabelitz, D., Meri, S., & Kalantar, K.
(2020). The Effects of Type 2 Diabetes Mellitus on Organ Metabolism and
the Immune System. Front Immunol, 11 , 1582.
doi:10.3389/fimmu.2020.01582
David, Z., Boyer, T. D., Wright, T. L., & Manns, M. P. (2006).Zakim and Boyer’s hepatology : a textbook of liver disease (5th
ed.). Philadelphia, PA: Saunders Elsevier.
De Silva, N. M. G., Borges, M. C., Hingorani, A. D., Engmann, J., Shah,
T., Zhang, X., . . . Lawlor, D. A. (2019). Liver Function and Risk of
Type 2 Diabetes: Bidirectional Mendelian Randomization Study.Diabetes, 68 (8), 1681-1691. doi:10.2337/db18-1048
Fahed, A. C., El-Hage-Sleiman, A. K., Farhat, T. I., & Nemer, G. M.
(2012). Diet, genetics, and disease: a focus on the middle East and
north Africa region. J Nutr Metab, 2012 , 109037.
doi:10.1155/2012/109037
Gesta, S., Tseng, Y. H., & Kahn, C. R. (2007). Developmental origin of
fat: tracking obesity to its source. Cell, 131 (2), 242-256.
doi:10.1016/j.cell.2007.10.004
Gwaltney-Brant, S. M. (2021). Chapter 8 - Nutraceuticals in hepatic
diseases. In R. C. Gupta, R. Lall, & A. Srivastava (Eds.),Nutraceuticals (Second Edition) (pp. 117-129): Academic Press.
Handa, P., Maliken, B. D., Nelson, J. E., Morgan-Stevenson, V., Messner,
D. J., Dhillon, B. K., . . . Kowdley, K. V. (2014). Reduced adiponectin
signaling due to weight gain results in nonalcoholic steatohepatitis
through impaired mitochondrial biogenesis. Hepatology, 60 (1),
133-145. doi:10.1002/hep.26946
Hasnain, S. Z., Borg, D. J., Harcourt, B. E., Tong, H., Sheng, Y. H.,
Ng, C. P., . . . McGuckin, M. A. (2014). Glycemic control in diabetes is
restored by therapeutic manipulation of cytokines that regulate beta
cell stress. Nat Med, 20 (12), 1417-1426. doi:10.1038/nm.3705
Howlader, M., Sultana, M. I., Akter, F., & Hossain, M. M. (2021).
Adiponectin gene polymorphisms associated with diabetes mellitus: A
descriptive review. Heliyon, 7 (8), e07851.
doi:10.1016/j.heliyon.2021.e07851
Inzucchi, S. E. (2002). Oral antihyperglycemic therapy for type 2
diabetes: scientific review. JAMA, 287 (3), 360-372.
doi:10.1001/jama.287.3.360
Iwabu, M., Yamauchi, T., Okada-Iwabu, M., Sato, K., Nakagawa, T.,
Funata, M., . . . Kadowaki, T. (2010). Adiponectin and AdipoR1 regulate
PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature,
464 (7293), 1313-1319. doi:10.1038/nature08991
Jager, S., Handschin, C., St-Pierre, J., & Spiegelman, B. M. (2007).
AMP-activated protein kinase (AMPK) action in skeletal muscle via direct
phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A, 104 (29),
12017-12022. doi:10.1073/pnas.0705070104
Karamian, M., Moossavi, M., & Hemmati, M. (2021). From diabetes to
renal aging: the therapeutic potential of adiponectin. J Physiol
Biochem, 77 (2), 205-214. doi:10.1007/s13105-021-00790-4
Kasper, D. L. (2015). Harrison’s principles of internal medicine(19th edition / editors, Dennis L. Kasper, Anthony S. Fauci, Stephen L.
Hauser, Dan L. Longo, J. Larry Jameson, Joseph Loscalzo. ed.). New York:
McGraw Hill Education Medical.
Kawano, J., & Arora, R. (2009). The role of adiponectin in obesity,
diabetes, and cardiovascular disease. J Cardiometab Syndr, 4 (1),
44-49. doi:CMS030 [pii]
10.1111/j.1559-4572.2008.00030.x
Kim, J. Y., Barua, S., Jeong, Y. J., & Lee, J. E. (2020). Adiponectin:
The Potential Regulator and Therapeutic Target of Obesity and
Alzheimer’s Disease. Int J Mol Sci, 21 (17).
doi:10.3390/ijms21176419
Kim, Y., Lim, J. H., Kim, M. Y., Kim, E. N., Yoon, H. E., Shin, S. J., .
. . Park, C. W. (2018). The Adiponectin Receptor Agonist AdipoRon
Ameliorates Diabetic Nephropathy in a Model of Type 2 Diabetes. J
Am Soc Nephrol, 29 (4), 1108-1127. doi:10.1681/ASN.2017060627
Leroith, D., & Accili, D. (2008). Mechanisms of disease: using
genetically altered mice to study concepts of type 2 diabetes. Nat
Clin Pract Endocrinol Metab, 4 (3), 164-172. doi:10.1038/ncpendmet0729
Liang, H., & Ward, W. F. (2006). PGC-1alpha: a key regulator of energy
metabolism. Adv Physiol Educ, 30 (4), 145-151.
doi:10.1152/advan.00052.2006
Lin, J., Wu, H., Tarr, P. T., Zhang, C. Y., Wu, Z., Boss, O., . . .
Spiegelman, B. M. (2002). Transcriptional co-activator PGC-1 alpha
drives the formation of slow-twitch muscle fibres. Nature,
418 (6899), 797-801. doi:10.1038/nature00904
Liu, Y., Trnka, M. J., Guan, S., Kwon, D., Kim, D. H., Chen, J. J., . .
. Correia, M. A. (2020). A Novel Mechanism for NF-kappaB-activation via
IkappaB-aggregation: Implications for Hepatic Mallory-Denk-Body Induced
Inflammation. Mol Cell Proteomics, 19 (12), 1968-1986.
doi:10.1074/mcp.RA120.002316
Mao, X., Kikani, C. K., Riojas, R. A., Langlais, P., Wang, L., Ramos, F.
J., . . . Dong, L. Q. (2006). APPL1 binds to adiponectin receptors and
mediates adiponectin signalling and function. Nat Cell Biol,
8 (5), 516-523. doi:10.1038/ncb1404
Marchesini, G., Moscatiello, S., Di Domizio, S., & Forlani, G. (2008).
Obesity-Associated Liver Disease. The Journal of Clinical
Endocrinology & Metabolism, 93 (11_supplement_1), s74-s80.
doi:10.1210/jc.2008-1399
Nigro, E., Scudiero, O., Monaco, M. L., Palmieri, A., Mazzarella, G.,
Costagliola, C., . . . Daniele, A. (2014). New insight into adiponectin
role in obesity and obesity-related diseases. Biomed Res Int,
2014 , 658913. doi:10.1155/2014/658913
Nikolajczyk, B. S., Jagannathan-Bogdan, M., Shin, H., & Gyurko, R.
(2011). State of the union between metabolism and the immune system in
type 2 diabetes. Genes Immun, 12 (4), 239-250.
doi:10.1038/gene.2011.14
Okada-Iwabu, M., Yamauchi, T., Iwabu, M., Honma, T., Hamagami, K.,
Matsuda, K., . . . Kadowaki, T. (2013). A small-molecule AdipoR agonist
for type 2 diabetes and short life in obesity. Nature, 503 (7477),
493-499. doi:10.1038/nature12656
Patti, M. E., Butte, A. J., Crunkhorn, S., Cusi, K., Berria, R.,
Kashyap, S., . . . Mandarino, L. J. (2003). Coordinated reduction of
genes of oxidative metabolism in humans with insulin resistance and
diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci U S
A, 100 (14), 8466-8471. doi:10.1073/pnas.1032913100
Qiu, W., Wu, H., Hu, Z., Wu, X., Tu, M., Fang, F., . . . Chen, J.
(2021). Identification and characterization of a novel adiponectin
receptor agonist adipo anti-inflammation agonist and its
anti-inflammatory effects in vitro and in vivo. Br J Pharmacol,
178 (2), 280-297. doi:10.1111/bph.15277
Rasmussen, M. S., Lihn, A. S., Pedersen, S. B., Bruun, J. M., Rasmussen,
M., & Richelsen, B. (2006). Adiponectin receptors in human adipose
tissue: effects of obesity, weight loss, and fat depots. Obesity
(Silver Spring), 14 (1), 28-35. doi:10.1038/oby.2006.5
Ruan, H., & Dong, L. Q. (2016). Adiponectin signaling and function in
insulin target tissues. J Mol Cell Biol, 8 (2), 101-109.
doi:10.1093/jmcb/mjw014
Ruderman, N. B., Carling, D., Prentki, M., & Cacicedo, J. M. (2013).
AMPK, insulin resistance, and the metabolic syndrome. J Clin
Invest, 123 (7), 2764-2772. doi:10.1172/JCI67227
Santamarina, A. B., Oliveira, J. L., Silva, F. P., Carnier, J.,
Mennitti, L. V., Santana, A. A., . . . Oyama, L. M. (2015). Green Tea
Extract Rich in Epigallocatechin-3-Gallate Prevents Fatty Liver by AMPK
Activation via LKB1 in Mice Fed a High-Fat Diet. PLoS One,
10 (11), e0141227. doi:10.1371/journal.pone.0141227
Shen, S. H., Singh, S. P., Raffaele, M., Waldman, M., Hochhauser, E.,
Ospino, J., . . . Peterson, S. J. (2022). Adipocyte-Specific Expression
of PGC1alpha Promotes Adipocyte Browning and Alleviates Obesity-Induced
Metabolic Dysfunction in an HO-1-Dependent Fashion. Antioxidants
(Basel), 11 (6). doi:10.3390/antiox11061147
Shi, J., Cao, B., Zha, W. B., Wu, X. L., Liu, L. S., Xiao, W. J., . . .
Liu, C. X. (2013). Pharmacokinetic interactions between
20(S)-ginsenoside Rh2 and the HIV protease inhibitor ritonavir in vitro
and in vivo. Acta Pharmacol Sin, 34 (10), 1349-1358.
doi:10.1038/aps.2013.69
Shoelson, S. E., Herrero, L., & Naaz, A. (2007). Obesity, inflammation,
and insulin resistance. Gastroenterology, 132 (6), 2169-2180.
doi:10.1053/j.gastro.2007.03.059
Shoelson, S. E., Lee, J., & Goldfine, A. B. (2006). Inflammation and
insulin resistance. J Clin Invest, 116 (7), 1793-1801.
doi:10.1172/JCI29069
Tomas, E., Tsao, T. S., Saha, A. K., Murrey, H. E., Zhang Cc, C., Itani,
S. I., . . . Ruderman, N. B. (2002). Enhanced muscle fat oxidation and
glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase
inhibition and AMP-activated protein kinase activation. Proc Natl
Acad Sci U S A, 99 (25), 16309-16313. doi:10.1073/pnas.222657499
Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.
A., Vogiatzi, G., Papaioannou, S., . . . Tousoulis, D. (2019). The Role
of Inflammation in Diabetes: Current Concepts and Future Perspectives.Eur Cardiol, 14 (1), 50-59. doi:10.15420/ecr.2018.33.1
Walker, B. R., & Colledge, N. R. (2013). Davidson’s principles
and practice of medicine e-book : Elsevier Health Sciences.
Wang, Y., Liu, H., Zhang, R., Xiang, Y., Lu, J., Xia, B., . . . Wu, J.
(2022). AdipoRon exerts opposing effects on insulin sensitivity via
fibroblast growth factor 21-mediated time-dependent mechanisms. J
Biol Chem, 298 (3), 101641. doi:10.1016/j.jbc.2022.101641
Weyer, C., Pratley, R. E., Salbe, A. D., Bogardus, C., Ravussin, E., &
Tataranni, P. A. (2000). Energy expenditure, fat oxidation, and body
weight regulation: a study of metabolic adaptation to long-term weight
change. J Clin Endocrinol Metab, 85 (3), 1087-1094.
doi:10.1210/jcem.85.3.6447
Whitehead, J. P., Richards, A. A., Hickman, I. J., Macdonald, G. A., &
Prins, J. B. (2006). Adiponectin–a key adipokine in the metabolic
syndrome. Diabetes Obes Metab, 8 (3), 264-280.
doi:10.1111/j.1463-1326.2005.00510.x
Wu, X., Sun, Y., Cui, R., Qiu, W., Zhang, J., Hu, Z., . . . Chen, J.
(2022). A novel adiponectin receptor agonist (AdipoAI) ameliorates type
2 diabetes-associated periodontitis by enhancing autophagy in
osteoclasts. J Periodontal Res, 57 (2), 381-391.
doi:10.1111/jre.12969
Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S.,
. . . Kadowaki, T. (2003). Cloning of adiponectin receptors that mediate
antidiabetic metabolic effects. Nature, 423 (6941), 762-769.
doi:10.1038/nature01705
nature01705 [pii]
Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., .
. . Kadowaki, T. (2002). Adiponectin stimulates glucose utilization and
fatty-acid oxidation by activating AMP-activated protein kinase.Nat Med, 8 (11), 1288-1295. doi:10.1038/nm788
nm788 [pii]
Yamauchi, T., Kamon, J., Waki, H., Imai, Y., Shimozawa, N., Hioki, K., .
. . Kadowaki, T. (2003). Globular adiponectin protected ob/ob mice from
diabetes and ApoE-deficient mice from atherosclerosis. J Biol
Chem, 278 (4), 2461-2468. doi:10.1074/jbc.M209033200
Yamauchi, T., Nio, Y., Maki, T., Kobayashi, M., Takazawa, T., Iwabu, M.,
. . . Kadowaki, T. (2007). Targeted disruption of AdipoR1 and AdipoR2
causes abrogation of adiponectin binding and metabolic actions.Nat Med, 13 (3), 332-339. doi:10.1038/nm1557